IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Rating) fell 7.5% during trading on Friday . The company traded as low as $14.52 and last traded at $14.58. 130,800 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 348,890 shares. The stock had previously closed at $15.76.
Wall Street Analysts Forecast Growth
A number of research firms have commented on IDYA. Capital One Financial began coverage on shares of IDEAYA Biosciences in a research report on Wednesday, December 28th. They issued an “overweight” rating and a $29.00 target price on the stock. Oppenheimer boosted their price target on shares of IDEAYA Biosciences from $22.00 to $26.00 in a research note on Monday, January 23rd. TheStreet upgraded shares of IDEAYA Biosciences from a “d+” rating to a “c-” rating in a research note on Thursday, February 2nd. Wedbush boosted their price target on shares of IDEAYA Biosciences to $30.00 in a research note on Wednesday, December 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $25.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, March 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, IDEAYA Biosciences has an average rating of “Moderate Buy” and an average target price of $28.22.
IDEAYA Biosciences Price Performance
The stock’s 50 day moving average is $17.20 and its two-hundred day moving average is $16.13. The stock has a market capitalization of $725.32 million, a PE ratio of -10.78 and a beta of 0.89.
Institutional Trading of IDEAYA Biosciences
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.